Etanercept for therapy-resistant macrophage activation syndrome

被引：36

作者：

Makay, Balahan ^{[1
]}

Yilmaz, Sebnem ^{[2
]}

Tuerkyilmaz, Zeynep ^{[3
]}

Uenal, Nurettin ^{[4
]}

Oeren, Hale ^{[2
]}

Uensal, Erbil ^{[1
]}

机构：

[1] Dokuz Eylul Univ, Dept Pediat Rheumatol, Fac Med, TR-35340 Izmir, Turkey

[2] Dokuz Eylul Univ, Dept Pediat Hematol, Fac Med, TR-35340 Izmir, Turkey

[3] Dokuz Eylul Univ, Dept Pediat, Fac Med, TR-35340 Izmir, Turkey

[4] Dokuz Eylul Univ, Dept Pediat Cardiol, Fac Med, TR-35340 Izmir, Turkey

来源：

PEDIATRIC BLOOD & CANCER | 2008年 / 50卷 / 02期

关键词：

etanercept; macrophage activation syndrome; TNF-alpha inhibition;

D O I：

10.1002/pbc.21019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of childhood rheumatic diseases, especially systemic onset juvenile idiopathic arthritis (SoJIA). We report a 4-year-old girl with probable SoJIA who presented with MAS. She did not respond to pulse methyl prednisolone and Cyclosporine A (CsA). She also failed to respond to intravenous immunoglobulin (IVIG) therapy. Etanercept was started, based on the observation of increased serum levels of tumor necrosis factor-alpha (TNF-alpha) in patients with MAS. Her condition improved following etanercept, suggesting that etanercept might have a therapeutic role in resistant MAS.

引用

页码：419 / 421

页数：3

共 19 条

[1]

Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A [J].

Abella, EM ;

Artrip, J ;

Schultz, K ;

Ravindranath, Y .

JOURNAL OF PEDIATRICS, 1997, 130 (03) :467-470

[2]

INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF EXPERIMENTAL T-CELL-MEDIATED AUTOIMMUNE-DISEASE - UP-REGULATION OF T-CELL PROLIFERATION AND DOWN-REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA SECRETION [J].

ACHIRON, A ;

MARGALIT, R ;

HERSHKOVIZ, R ;

MARKOVITS, D ;

RESHEF, T ;

MELAMED, E ;

COHEN, IR ;

LIDER, O .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :600-605

[3]

Aeberli D, 2002, SWISS MED WKLY, V132, P414

[4]

Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab [J].

Aouba, A ;

De Bandt, M ;

Aslangul, E ;

Atkhen, N ;

Patri, B .

RHEUMATOLOGY, 2003, 42 (06) :800-U3

[5]

CASSIDY JT, 2001, TXB PEDIAT RHEUMATOL, P218

[6]

DeBenedetti F, 1997, BRIT J RHEUMATOL, V36, P581

[7]

Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis [J].

Egeler, RM ;

Shapiro, R ;

Loechelt, B ;

Filipovich, A .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1996, 18 (04) :340-345

[8]

Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome [J].

Grom, AA ;

Villanueva, J ;

Lee, S ;

Goldmuntz, EA ;

Passo, MH ;

Filipovich, A .

JOURNAL OF PEDIATRICS, 2003, 142 (03) :292-296

[9]

Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? [J].

Grom, AA .

CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (05) :587-590

[10]

Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases [J].

Mouy, R ;

Stephan, JL ;

Pillet, P ;

Haddad, E ;

Hubert, P ;

Prieur, AM .

JOURNAL OF PEDIATRICS, 1996, 129 (05) :750-754

← 1 2 →